| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5456925 | GLAXOSMITHKLINE | Pharmaceutical compositions containing furan derivatives |
Oct, 2012
(11 years ago) | |
| US5601848 | GLAXOSMITHKLINE | Methods for the treatment of gastrointestinal disorders |
Feb, 2014
(10 years ago) | |
| US5629297 | GLAXOSMITHKLINE | Medicament for treating gastrointestinal disorders |
May, 2014
(9 years ago) | |
Tritec is owned by Glaxosmithkline.
Tritec contains Ranitidine Bismuth Citrate.
Tritec has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Tritec are:
- US5456925
- US5601848
- US5629297
Tritec was authorised for market use on 08 August, 1996.
Tritec is available in tablet;oral dosage forms.
Tritec can be used as method for treating gi disorders caused by h. pylori which comprises administration of ranitidine bismuth citrate and clarithromycin for a greater than additive effect, method of treating peptic ulcer disease caused by campylobacter pyloridis comprising oral administration of 50 to 5,000mg bismuth daily for 3-56 days.
The generics of Tritec are possible to be released after 13 May, 2014.
Drugs and Companies using RANITIDINE BISMUTH CITRATE ingredient
Market Authorisation Date: 08 August, 1996
Treatment: Method of treating peptic ulcer disease caused by campylobacter pyloridis comprising oral administration of 50 to 5,000mg bismuth daily for 3-56 days; Method for treating gi disorders caused by h. pyl...
Dosage: TABLET;ORAL
TRITEC family patents
